News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
simplywall.st Market update
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Pulse Biosciences (PLSE) recently announced a $75 million at-the-market equity offering and reported wider second-quarter losses, impacting existing shareholders. Despite strong recent share price performance, with a 30-day return of 55.30% and a year-to-date return of 232.64%, the stock now trades above the latest …
Image source: The Motley Fool. DATE Thursday, Aug. 6, 2026 at 4:30 p.m. ET CALL PARTICIPANTS Investor Relations - Philip TaylorCo-Chair of the Board and Chief Executive Officer - Paul LaVioletteChief Financial Officer - Jon SkinnerCo-Chair of the Board - Bob Duggan Need a …
Kayne Anderson Rudnick Investment Management, LLC has filed an amended Schedule 13G, revealing a passive ownership stake of 4,694,472 shares in UL Solutions Inc. This represents 6.0% of the common stock. The filing details the firm's sole and shared voting and dispositive powers over …
Pulse Biosciences (NASDAQ:PLSE) stock reached a new 52-week high of $46.03, closing at $46.75, despite reporting weaker-than-expected quarterly results. Analyst sentiment is mixed, with a "Moderate Buy" consensus but an average price target below the current trading price. Institutional investors hold a significant 76.95% …
Pulse Biosciences Inc. (PLSE) stock hit an all-time high of $46.03, currently trading near its 52-week high of $45.90, despite a recent report of wider-than-expected Q2 2026 losses and lower revenue. The stock has seen a significant 163.78% one-year increase and 216% year-to-date, boosting …
UL Solutions Inc. (NYSE:ULS) reported robust headline earnings, but Simply Wall St's analysis suggests these profits were significantly boosted by US$154 million in "unusual items." These one-off contributions may lead to a profit drop in the current year if not repeated, indicating that the …
Pulse Biosciences, Inc. (PLSE) is developing next-generation nsPFA technology for AFib treatment, demonstrating high efficacy and efficiency. The company's leadership, strong clinical data, competitive position, and partnership strategy are expected to drive broad clinical adoption. This information is based on an audio transcript from …
UL Solutions (ULS) reported strong Q2 2026 earnings with sales of US$816 million and net income of US$246 million, reaffirming its full-year outlook. Despite a recent share price pullback, Simply Wall St suggests the stock could be 20.4% undervalued, with a fair value narrative …
UL Solutions Inc. director Shannon M. James reported a bona fide gift of 600 shares of Class A Common Stock on August 6, 2026. The transaction had a reported per-share value of $0.0000, indicating no consideration was received. Following this gift, James directly holds …
NORTHBROOK, Ill., August 10, 2026--(BUSINESS WIRE)--UL Solutions Inc. (NYSE: ULS), a global leader in applied safety science, today announced that senior management of the company will attend the following investor conferences: Wells Fargo 10th Annual Business, Info & IT Services Forum, Aug. 11 Jefferies …
Pulse Biosciences (PLSE) is under scrutiny after reporting a wider quarterly net loss and a US$75 million equity offering, despite its NANOPULSE-AF Study reaching its enrollment midpoint. The stock has seen significant gains, but analysts are concerned about its valuation, with a fair value …
Key Points Interested in UL Solutions Inc.? Here are five stocks we like better. Strong Q2 performance: Revenue increased 5.2% to $816 million, while adjusted EBITDA rose 11.2% to a record $219 million and adjusted EPS grew 13.5% to $0.59. Organic revenue growth reached …
UL Solutions (ULS) reported a strong Q2 2026 earnings beat with sales of US$816 million and net income rising to US$246 million, and diluted EPS increasing to US$1.21. Despite this surge in profitability and margin expansion, the stock was down 14.7% because earnings are …
Wall Street Zen has downgraded Pulse Biosciences (NASDAQ:PLSE) from "hold" to "sell," despite a broader analyst consensus of "Moderate Buy" with an average price target of $32.33. The company's stock opened at $42.41, up 10.9%, but it missed analyst expectations for its last quarterly …
Pulse Biosciences (NASDAQ:PLSE) experienced a 15.7% surge in its stock price, reaching approximately $44.26, despite a 51% drop in trading volume. The company holds a "Moderate Buy" consensus from analysts, though its average price target of $32.33 is below the current share price. This …
UL Solutions Inc. (NYSE:ULS) recently surpassed earnings expectations, delivering a profit of US$1.21 per share, significantly higher than forecasted, despite a 17% stock drop in the week following the results. While revenue estimates for 2026 remained unchanged at US$3.21 billion, analysts substantially increased their …
PULSE BIOSCIENCES, INC. reported product revenue of $434K and a net loss of ($24.66M) or diluted loss per share of ($0.36) for the current quarter of 2026. This compares to no product revenue and a ($19.17M) net loss or ($0.28) per share in the …
This article announces the filing of a Form 8K by Pulse Biosciences Inc. on August 6th. The brief notice from Investing.com indicates that the information pertains to the company's financial activities or significant events as required by the SEC.
Pulse Biosciences announced its business updates and financial results for the second quarter ended June 30, 2026, highlighting significant progress in its cardiac catheter program. The company surpassed the halfway point of enrollment in its U.S. pivotal NANOPULSE-AF study, raising $46.8 million in net …
Pulse Biosciences (PLSE) reported a Q2 loss of $0.36 per share, missing the Zacks Consensus Estimate of a $0.31 loss and underperforming the previous year's loss of $0.28 per share. The company also missed revenue estimates, posting $0.43 million against a 38% higher Zacks …
Pulse Biosciences has entered into an equity distribution agreement with Mizuho Securities USA LLC, allowing it to offer and sell up to $75 million in common stock. Mizuho will act as the sales agent, receiving a commission of up to 3.0% on shares sold. …
Pulse Biosciences Inc (PLSE) reported accelerated enrollment in its NanoPulse-AF IDE study, reaching the halfway point ahead of schedule, with strong feasibility data presented at HRS. The company strengthened its balance sheet by raising $57.5 million, extending its financial runway, and is progressing multiple …
Pulse Biosciences reported a wider-than-expected Q2 2026 loss and lower revenue but saw its stock rise after hours due to accelerated enrollment in its atrial fibrillation trial, a stronger cash position, and progress in its thyroid and surgical programs. The company's nanosecond pulsed field …
CALGARY, Alberta, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Pulse Seismic Inc. (TSX:PSD) (OTCQX:PLSDF) (“Pulse” or the “Company”) announces a CEO transition effective August 6, 2026. Pamela Wicks, CPA, ICD.D, currently Vice President, Finance and Chief Financial Officer, has been appointed President and Chief Executive …
Search by ticker symbol or company name and select a result to open its chart.